SG11201809729XA - Palpable marker composition - Google Patents
Palpable marker compositionInfo
- Publication number
- SG11201809729XA SG11201809729XA SG11201809729XA SG11201809729XA SG11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- composition
- administration
- kgs
- human
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 239000003550 marker Substances 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 abstract 3
- 150000001720 carbohydrates Chemical class 0.000 abstract 3
- 235000014633 carbohydrates Nutrition 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- 238000006469 Jacobsen epoxidation reaction Methods 0.000 abstract 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 abstract 1
- 150000002597 lactoses Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 150000004044 tetrasaccharides Chemical class 0.000 abstract 1
- 150000004043 trisaccharides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
GCr GC GC N O N C () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit VIII Hot 0 mu H H mo iflo oimIE (10) International Publication Number WO 2017/198858 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61K 47/26 (2006.01) (21) International Application Number: PCT/EP2017/062181 (22) International Filing Date: 19 May 2017 (19.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1650695-8 20 May 2016 (20.05.2016) SE (71) Applicants: TECHNICAL UNIVERSITY OF DEN- MARK [DK/DK]; Anker Engelunds Vej 1, 2800 Kgs. Lyn- gby (DK). NANOVI RADIOTHERAPY APS [DK/DK]; Diplomvej 373 N, 2800 Kgs. Lyngby (DK). (72) Inventors: ANDRESEN, Thomas Lars; Krogebjerg 68, 2720 Vanlose (DK). IRMING JOLCK, Rasmus; Bud- dingevej 25B, 2800 Kgs. Lyngby (DK). BRUUN, Linda Maria; Robert Jacobsens Vej 95, 2 TV, 2300 Copenhagen S (DK). (74) Agent: AWAPATENT AB; Box 5117, 200 71 Malmo (SE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: PALPABLE MARKER COMPOSITION Sacrifice Group A Sacrifice Group C: n = 3) n = 3 Injection of Sacrifice G , oup B marker (1 = 3) lh 3fi 24h Figure 1. (57) : The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffmose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration. [Continued on next page] WO 2017/198858 Al MIDEDIM01101 DIDIRMEM1111111111111111111111111H1101111111111111111111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650695 | 2016-05-20 | ||
| PCT/EP2017/062181 WO2017198858A1 (en) | 2016-05-20 | 2017-05-19 | Palpable marker composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809729XA true SG11201809729XA (en) | 2018-12-28 |
Family
ID=59070598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809729XA SG11201809729XA (en) | 2016-05-20 | 2017-05-19 | Palpable marker composition |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11058780B2 (en) |
| EP (1) | EP3458029A1 (en) |
| JP (1) | JP7086863B2 (en) |
| KR (1) | KR102358040B1 (en) |
| CN (1) | CN109475491B (en) |
| AU (1) | AU2017266410B2 (en) |
| BR (1) | BR112018073493A2 (en) |
| CA (1) | CA3023928A1 (en) |
| IL (1) | IL263071B (en) |
| MX (1) | MX2018014087A (en) |
| SG (1) | SG11201809729XA (en) |
| WO (1) | WO2017198858A1 (en) |
| ZA (1) | ZA201808532B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018168282A1 (en) | 2017-03-15 | 2018-09-20 | 株式会社村田製作所 | Circuit module, network module, and automotive electronic device |
| US20210275692A1 (en) * | 2018-06-19 | 2021-09-09 | Danmarks Tekniske Universitet | Solution comprising fluorescent dye as fiducial marker |
| WO2019243419A1 (en) * | 2018-06-19 | 2019-12-26 | Danmarks Tekniske Universitet | Brachygel for treatment of cancer and/or for guidance of surgery |
| CA3143104A1 (en) * | 2019-06-12 | 2020-12-17 | Technical University Of Denmark | Dissacharide formulations for controlled drug release |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3733397A (en) | 1966-12-02 | 1973-05-15 | Pharmacia Ab | Method for the x-ray visualization of body cavities and a preparation for carrying out the method |
| SE344166B (en) | 1966-12-13 | 1972-04-04 | Pharmacia Ab | |
| US3804892A (en) | 1967-12-28 | 1974-04-16 | Pharmacia Ab | Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof |
| SE315974B (en) | 1967-12-28 | 1969-10-13 | Pharmacia Ab | |
| US3763227A (en) | 1967-12-28 | 1973-10-02 | Pharmacia Ab | Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof |
| DE2628517C2 (en) | 1976-06-23 | 1985-02-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | Dicarboxylic acid bis (3,5-dicarbamoyl-2,4,6-triiodanilide) compounds, process for their preparation and X-ray contrast media |
| US4406878A (en) | 1978-08-02 | 1983-09-27 | Eastman Kodak Company | Iodinated contrast agent for radiography |
| IT1207226B (en) | 1979-08-09 | 1989-05-17 | Bracco Ind Chimica Spa | 2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM. |
| DE3038853A1 (en) | 1980-10-10 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | NEW N-HYDROXY-ALKYLATED DICARBONIC ACID-BIS- (3,5-DICARBAMOYL-2,4,6-TRIJODANILIDES), THEIR PRODUCTION AND THEIR CONTAINING X-RAY CONTRAST AGENTS (II) |
| US4439356A (en) | 1981-03-03 | 1984-03-27 | Syva Company | Unsymmetrical fluorescein derivatives |
| DE3364536D1 (en) | 1982-11-08 | 1986-08-21 | Nyegaard & Co As | X-ray contrast agents |
| US5198136A (en) | 1986-12-23 | 1993-03-30 | Daikin Industries Ltd. | Iodine-containing compound, preparation thereof and block copolymer comprising the same |
| US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
| IT1245853B (en) | 1990-11-16 | 1994-10-25 | Bracco Spa | 1,3-BIS (3- (MONO OR POLYHYDROXY) ACYLAMINE-5- (MONO OR POLYHYDROXY-ALCHYL) AMINOCARBONYL-2,4,6-TRIIODE-BENZOYL-AMINO) -HYDROXY- OR HYDROXY-ALCHYL-PROPANE, THEIR METHOD OF PREPARATION AND ROENTGENOGRAPHIC CONTRAST MEANS THAT CONTAIN THEM |
| US5750409A (en) | 1991-11-18 | 1998-05-12 | Boehringer Mannheim Gmbh | Pentacyclic compounds and their use as absorption or fluorescent dyes |
| DK0615438T3 (en) * | 1991-12-05 | 1996-11-11 | Mallinckrodt Veterinary Inc | A carbohydrate glass matrix for long-term release of a therapeutic agent |
| GB9303992D0 (en) | 1993-02-26 | 1993-04-14 | Nycomed Imaging As | Contrast agents |
| PT1006935E (en) | 1995-06-07 | 2005-06-30 | Durect Corp | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM |
| US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| AU6114396A (en) | 1995-06-16 | 1997-01-15 | Biophysica Foundation | Formyl derivatives as nonionic contrast media |
| US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
| US6270464B1 (en) * | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
| US6072069A (en) | 1998-11-04 | 2000-06-06 | Biophysica, Inc. | Biodegradable nonionic contrast media |
| BR9906240A (en) | 1999-06-28 | 2002-07-23 | Temis Lostalo S A Lab | Injectable charcoal compositions, in stable aqueous suspension, method for preparing them and pre-surgical marking method in the investigation of non-palpable breast pathologies applying the aforementioned compositions, use of activated carbon of selective granulometry for the preparation of said compositions |
| EP1186305A1 (en) | 2000-09-07 | 2002-03-13 | Schering Aktiengesellschaft | New brominated compounds as contrast media for X-ray mammography |
| WO2003080554A2 (en) | 2002-03-27 | 2003-10-02 | Fuji Photo Film Co., Ltd. | Iodinated triglyceride analogs |
| US20050255045A1 (en) | 2004-05-13 | 2005-11-17 | Woltering Eugene A | Surgical marking composition and method |
| EP2231200A1 (en) | 2007-12-05 | 2010-09-29 | GE Healthcare AS | Contrast agents |
| US20090217932A1 (en) | 2008-03-03 | 2009-09-03 | Ethicon Endo-Surgery, Inc. | Intraluminal tissue markers |
| US10064960B2 (en) * | 2011-11-25 | 2018-09-04 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
| KR102242406B1 (en) * | 2013-05-24 | 2021-04-21 | 덴마크스 텍니스케 유니버시테트 | Gel formulations for guiding radiotherapy |
| WO2016079332A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for improving immunotherapy |
| WO2016079331A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for enhancing the effect of radiotherapy |
| CN107249570B (en) * | 2014-11-21 | 2022-08-09 | 丹麦技术大学 | Gel formulations for topical drug delivery |
-
2017
- 2017-05-19 CA CA3023928A patent/CA3023928A1/en active Pending
- 2017-05-19 JP JP2018561005A patent/JP7086863B2/en active Active
- 2017-05-19 WO PCT/EP2017/062181 patent/WO2017198858A1/en unknown
- 2017-05-19 EP EP17730679.2A patent/EP3458029A1/en not_active Withdrawn
- 2017-05-19 KR KR1020187035677A patent/KR102358040B1/en active IP Right Grant
- 2017-05-19 SG SG11201809729XA patent/SG11201809729XA/en unknown
- 2017-05-19 MX MX2018014087A patent/MX2018014087A/en unknown
- 2017-05-19 CN CN201780023259.XA patent/CN109475491B/en not_active Expired - Fee Related
- 2017-05-19 BR BR112018073493-4A patent/BR112018073493A2/en not_active Application Discontinuation
- 2017-05-19 US US16/302,517 patent/US11058780B2/en active Active
- 2017-05-19 AU AU2017266410A patent/AU2017266410B2/en not_active Ceased
-
2018
- 2018-11-18 IL IL263071A patent/IL263071B/en unknown
- 2018-12-18 ZA ZA2018/08532A patent/ZA201808532B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017266410B2 (en) | 2022-07-14 |
| MX2018014087A (en) | 2019-06-10 |
| EP3458029A1 (en) | 2019-03-27 |
| US20190275174A1 (en) | 2019-09-12 |
| KR102358040B1 (en) | 2022-01-28 |
| IL263071B (en) | 2021-12-01 |
| AU2017266410A1 (en) | 2018-11-22 |
| BR112018073493A2 (en) | 2019-03-26 |
| JP2019519522A (en) | 2019-07-11 |
| US11058780B2 (en) | 2021-07-13 |
| KR20190026662A (en) | 2019-03-13 |
| CA3023928A1 (en) | 2017-11-23 |
| CN109475491A (en) | 2019-03-15 |
| CN109475491B (en) | 2022-06-24 |
| IL263071A (en) | 2018-12-31 |
| WO2017198858A1 (en) | 2017-11-23 |
| ZA201808532B (en) | 2020-02-26 |
| JP7086863B2 (en) | 2022-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201809729XA (en) | Palpable marker composition | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |